Loading
companiesCompany
Advanced Accelerator Applications (Novartis)
The CERN spin-out that Novartis bought in 2018 for Lutathera, which now makes Pluvicto and the Locametz and Netspot imaging kits.
Overview
Advanced Accelerator Applications, based in Saint-Genis-Pouilly, France, and founded in 2002, is the CERN spin-out that Novartis bought in 2018 for Lutathera, and it now makes Pluvicto and the Locametz and Netspot imaging kits. AAA developed Lutathera, or 177Lu-DOTATATE, and the Netspot gallium-68 DOTATATE kit before its 3.9 billion dollar acquisition, and as Novartis' radioligand unit it manufactures Locametz, the gallium-68 PSMA-11 kit, and Pluvicto and runs the Novartis radioligand production network in Europe and the United States. OnCo links it to prostate cancer and neuroendocrine tumours, to PSMA PET, somatostatin receptor PET and beta-emitter radioligand therapy, and to Novartis. Whether its production network can meet demand as radioligand indications widen is the open question. Locametz and Pluvicto have their own pages.
Headquarters
Saint-Genis-Pouilly, FR
Scorecard
All companies#95of 1244 companies, score 51
- approved products +18
- phase 1/2 +1
- targets +4
- modalities +6
- regions +5
- 24-month regulatory events +4
- registry trials +13
3 approved, 0 in phase 3, 1 earlier, 2 targets, 41 registry studies. Formula on the scorecards page.
Website
Founded
2002
ApprovedPET imaging agent kit (PSMA, gallium-68)
Locametz (kit for Ga-68 gozetotide) · Locametz
Novartis' gallium PSMA scan kit, approved the same day as Pluvicto as the test that qualifies men for that radioactive drug.
ApprovedPET radiotracer (somatostatin receptor ligand)
Gallium-68 DOTATATE (and Cu-64 DOTATATE) · Netspot / Detectnet
The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).
ApprovedRadioligand therapy (beta)
Lutetium-177 vipivotide tetraxetan · Pluvicto
A radioactive drug that seeks out PSMA on prostate cancer cells; the best-selling radiopharmaceutical ever.
Phase 2Small-molecule inhibitor
AMO959 is a small-molecule inhibitor from Novartis Pharmaceuticals, in registered phase 2 trials for prostate cancer.
Similar pages
- TreatmentAsciminib
Shares Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia, Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib., Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia, Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP.
- TreatmentAlpelisib
Shares Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation., Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer, Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer, Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation.
- TechnologyPI3K, AKT and mTOR inhibitors
Shares Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation., Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer, Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer, Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation.
- CancerChronic myeloid leukaemia, chronic phase
Shares Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia, Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia, Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP, A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP).
- TermTheranostics
Shares Locametz (kit for Ga-68 gozetotide), Gallium-68 DOTATATE (and Cu-64 DOTATATE), Somatostatin receptor PET (68Ga/64Cu-DOTATATE), PSMA PET.
- CancerChronic myeloid leukaemia (CML)
Shares Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia, Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib., Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia, Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP.
- TreatmentJDQ443
Shares Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation., Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation, Novartis.
- TrialVISION
Shares Locametz (kit for Ga-68 gozetotide), Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
cancers
fronts
technologies
drugs
Phase 2Small-molecule inhibitor
ApprovedPET radiotracer (somatostatin receptor ligand)
Gallium-68 DOTATATE (and Cu-64 DOTATATE) · Netspot / Detectnet
ApprovedPET imaging agent kit (PSMA, gallium-68)
Locametz (kit for Ga-68 gozetotide) · Locametz
ApprovedRadioligand therapy (beta)
Lutetium-177 vipivotide tetraxetan · Pluvicto
companies
trials
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AMLA Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant MelanomasA Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCA Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate CancerA Study of 177Lu-FAP-2286 in Advanced Solid TumorsA Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPA Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous LeukemiaClinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerPan Tumor Rollover StudyPhase IIIb Study of Ribociclib + ET in Early Breast CancerRibociclib (LEE011) Rollover Study for Continued AccessRoll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast CancerStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast CancerStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA MutationStudy of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive PatientsStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationStudy of LEE011, BYL719 and Letrozole in Advanced ER+ Breast CancerStudy to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment AloneStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPStudy to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NETStudy to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET